Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial

Terence T. Sio, Jennifer Le-Rademacher, James L. Leenstra, Charles Lawrence Loprinzi, Grant Rine, Amarinthia Curtis, Anurag K. Singh, James A. Martenson, Paul J. Novotny, Angelina D. Tan, Rui Qin, Stephen J. Ko, Paul L. Reiter, Robert C. Miller

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Importance: Oral mucositis causes substantial morbidity during head and neck radiotherapy. In a randomized study, doxepin mouthwash was shown to reduce oral mucositis-related pain. A common mouthwash comprising diphenhydramine-lidocaine-antacid is also widely used. Objective: To evaluate the effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash for the treatment of oral mucositis-related pain. Design, Setting, and Participants: A phase 3 randomized trial was conducted from November 1, 2014, to May 16, 2016, at 30 US institutions and included 275 patients who underwent definitive head and neck radiotherapy, had an oral mucositis pain score of 4 points or greater (scale, 0-10), and were followed up for a maximum of 28 days. Interventions: Ninety-two patients were randomized to doxepin mouthwash (25 mg/5 mL water); 91 patients to diphenhydramine-lidocaine-antacid; and 92 patients to placebo. Main Outcome and Measures: The primary end point was total oral mucositis pain reduction (defined by the area under the curve and adjusted for baseline pain score) during the 4 hours after a single dose of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash compared with a single dose of placebo. The minimal clinically important difference was a 3.5-point change. The secondary end points included drowsiness, unpleasant taste, and stinging or burning. All scales ranged from 0 (best) to 10 (worst). Results: Among the 275 patients randomized (median age, 61 years; 58 [21%] women), 227 (83%) completed treatment per protocol. Mucositis pain during the first 4 hours decreased by 11.6 points in the doxepin mouthwash group, by 11.7 points in the diphenhydramine-lidocaine-antacid mouthwash group, and by 8.7 points in the placebo group. The between-group difference was 2.9 points (95% CI, 0.2-6.0; P =.02) for doxepin mouthwash vs placebo and 3.0 points (95% CI, 0.1-5.9; P =.004) for diphenhydramine-lidocaine-antacid mouthwash vs placebo. More drowsiness was reported with doxepin mouthwash vs placebo (by 1.5 points [95% CI, 0-4.0]; P =.03), unpleasant taste (by 1.5 points [95% CI, 0-3.0]; P =.002), and stinging or burning (by 4.0 points [95% CI, 2.5-5.0]; P <.001). Maximum grade 3 adverse events for the doxepin mouthwash occurred in 3 patients (4%); diphenhydramine-lidocaine-antacid mouthwash, 3 (4%); and placebo, 2 (2%). Fatigue was reported by 5 patients (6%) in the doxepin mouthwash group and no patients in the diphenhydramine-lidocaine-antacid mouthwash group. Conclusions and Relevance: Among patients undergoing head and neck radiotherapy, the use of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo significantly reduced oral mucositis pain during the first 4 hours after administration; however, the effect size was less than the minimal clinically important difference. Further research is needed to assess longer-term efficacy and safety for both mouthwashes. Trial Registration: ClinicalTrials.gov Identifier: NCT02229539.

Original languageEnglish (US)
Pages (from-to)1481-1490
Number of pages10
JournalJAMA - Journal of the American Medical Association
Volume321
Issue number15
DOIs
StatePublished - Apr 16 2019

Fingerprint

Doxepin
Mouthwashes
Diphenhydramine
Antacids
Stomatitis
Lidocaine
Radiotherapy
Randomized Controlled Trials
Placebos
Pain
Neck
Sleep Stages
Head

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain : The Alliance A221304 Randomized Clinical Trial. / Sio, Terence T.; Le-Rademacher, Jennifer; Leenstra, James L.; Loprinzi, Charles Lawrence; Rine, Grant; Curtis, Amarinthia; Singh, Anurag K.; Martenson, James A.; Novotny, Paul J.; Tan, Angelina D.; Qin, Rui; Ko, Stephen J.; Reiter, Paul L.; Miller, Robert C.

In: JAMA - Journal of the American Medical Association, Vol. 321, No. 15, 16.04.2019, p. 1481-1490.

Research output: Contribution to journalArticle

Sio, Terence T. ; Le-Rademacher, Jennifer ; Leenstra, James L. ; Loprinzi, Charles Lawrence ; Rine, Grant ; Curtis, Amarinthia ; Singh, Anurag K. ; Martenson, James A. ; Novotny, Paul J. ; Tan, Angelina D. ; Qin, Rui ; Ko, Stephen J. ; Reiter, Paul L. ; Miller, Robert C. / Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain : The Alliance A221304 Randomized Clinical Trial. In: JAMA - Journal of the American Medical Association. 2019 ; Vol. 321, No. 15. pp. 1481-1490.
@article{55cc7d8679c34e269864b36b337a6b9b,
title = "Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial",
abstract = "Importance: Oral mucositis causes substantial morbidity during head and neck radiotherapy. In a randomized study, doxepin mouthwash was shown to reduce oral mucositis-related pain. A common mouthwash comprising diphenhydramine-lidocaine-antacid is also widely used. Objective: To evaluate the effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash for the treatment of oral mucositis-related pain. Design, Setting, and Participants: A phase 3 randomized trial was conducted from November 1, 2014, to May 16, 2016, at 30 US institutions and included 275 patients who underwent definitive head and neck radiotherapy, had an oral mucositis pain score of 4 points or greater (scale, 0-10), and were followed up for a maximum of 28 days. Interventions: Ninety-two patients were randomized to doxepin mouthwash (25 mg/5 mL water); 91 patients to diphenhydramine-lidocaine-antacid; and 92 patients to placebo. Main Outcome and Measures: The primary end point was total oral mucositis pain reduction (defined by the area under the curve and adjusted for baseline pain score) during the 4 hours after a single dose of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash compared with a single dose of placebo. The minimal clinically important difference was a 3.5-point change. The secondary end points included drowsiness, unpleasant taste, and stinging or burning. All scales ranged from 0 (best) to 10 (worst). Results: Among the 275 patients randomized (median age, 61 years; 58 [21{\%}] women), 227 (83{\%}) completed treatment per protocol. Mucositis pain during the first 4 hours decreased by 11.6 points in the doxepin mouthwash group, by 11.7 points in the diphenhydramine-lidocaine-antacid mouthwash group, and by 8.7 points in the placebo group. The between-group difference was 2.9 points (95{\%} CI, 0.2-6.0; P =.02) for doxepin mouthwash vs placebo and 3.0 points (95{\%} CI, 0.1-5.9; P =.004) for diphenhydramine-lidocaine-antacid mouthwash vs placebo. More drowsiness was reported with doxepin mouthwash vs placebo (by 1.5 points [95{\%} CI, 0-4.0]; P =.03), unpleasant taste (by 1.5 points [95{\%} CI, 0-3.0]; P =.002), and stinging or burning (by 4.0 points [95{\%} CI, 2.5-5.0]; P <.001). Maximum grade 3 adverse events for the doxepin mouthwash occurred in 3 patients (4{\%}); diphenhydramine-lidocaine-antacid mouthwash, 3 (4{\%}); and placebo, 2 (2{\%}). Fatigue was reported by 5 patients (6{\%}) in the doxepin mouthwash group and no patients in the diphenhydramine-lidocaine-antacid mouthwash group. Conclusions and Relevance: Among patients undergoing head and neck radiotherapy, the use of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo significantly reduced oral mucositis pain during the first 4 hours after administration; however, the effect size was less than the minimal clinically important difference. Further research is needed to assess longer-term efficacy and safety for both mouthwashes. Trial Registration: ClinicalTrials.gov Identifier: NCT02229539.",
author = "Sio, {Terence T.} and Jennifer Le-Rademacher and Leenstra, {James L.} and Loprinzi, {Charles Lawrence} and Grant Rine and Amarinthia Curtis and Singh, {Anurag K.} and Martenson, {James A.} and Novotny, {Paul J.} and Tan, {Angelina D.} and Rui Qin and Ko, {Stephen J.} and Reiter, {Paul L.} and Miller, {Robert C.}",
year = "2019",
month = "4",
day = "16",
doi = "10.1001/jama.2019.3504",
language = "English (US)",
volume = "321",
pages = "1481--1490",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "15",

}

TY - JOUR

T1 - Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain

T2 - The Alliance A221304 Randomized Clinical Trial

AU - Sio, Terence T.

AU - Le-Rademacher, Jennifer

AU - Leenstra, James L.

AU - Loprinzi, Charles Lawrence

AU - Rine, Grant

AU - Curtis, Amarinthia

AU - Singh, Anurag K.

AU - Martenson, James A.

AU - Novotny, Paul J.

AU - Tan, Angelina D.

AU - Qin, Rui

AU - Ko, Stephen J.

AU - Reiter, Paul L.

AU - Miller, Robert C.

PY - 2019/4/16

Y1 - 2019/4/16

N2 - Importance: Oral mucositis causes substantial morbidity during head and neck radiotherapy. In a randomized study, doxepin mouthwash was shown to reduce oral mucositis-related pain. A common mouthwash comprising diphenhydramine-lidocaine-antacid is also widely used. Objective: To evaluate the effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash for the treatment of oral mucositis-related pain. Design, Setting, and Participants: A phase 3 randomized trial was conducted from November 1, 2014, to May 16, 2016, at 30 US institutions and included 275 patients who underwent definitive head and neck radiotherapy, had an oral mucositis pain score of 4 points or greater (scale, 0-10), and were followed up for a maximum of 28 days. Interventions: Ninety-two patients were randomized to doxepin mouthwash (25 mg/5 mL water); 91 patients to diphenhydramine-lidocaine-antacid; and 92 patients to placebo. Main Outcome and Measures: The primary end point was total oral mucositis pain reduction (defined by the area under the curve and adjusted for baseline pain score) during the 4 hours after a single dose of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash compared with a single dose of placebo. The minimal clinically important difference was a 3.5-point change. The secondary end points included drowsiness, unpleasant taste, and stinging or burning. All scales ranged from 0 (best) to 10 (worst). Results: Among the 275 patients randomized (median age, 61 years; 58 [21%] women), 227 (83%) completed treatment per protocol. Mucositis pain during the first 4 hours decreased by 11.6 points in the doxepin mouthwash group, by 11.7 points in the diphenhydramine-lidocaine-antacid mouthwash group, and by 8.7 points in the placebo group. The between-group difference was 2.9 points (95% CI, 0.2-6.0; P =.02) for doxepin mouthwash vs placebo and 3.0 points (95% CI, 0.1-5.9; P =.004) for diphenhydramine-lidocaine-antacid mouthwash vs placebo. More drowsiness was reported with doxepin mouthwash vs placebo (by 1.5 points [95% CI, 0-4.0]; P =.03), unpleasant taste (by 1.5 points [95% CI, 0-3.0]; P =.002), and stinging or burning (by 4.0 points [95% CI, 2.5-5.0]; P <.001). Maximum grade 3 adverse events for the doxepin mouthwash occurred in 3 patients (4%); diphenhydramine-lidocaine-antacid mouthwash, 3 (4%); and placebo, 2 (2%). Fatigue was reported by 5 patients (6%) in the doxepin mouthwash group and no patients in the diphenhydramine-lidocaine-antacid mouthwash group. Conclusions and Relevance: Among patients undergoing head and neck radiotherapy, the use of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo significantly reduced oral mucositis pain during the first 4 hours after administration; however, the effect size was less than the minimal clinically important difference. Further research is needed to assess longer-term efficacy and safety for both mouthwashes. Trial Registration: ClinicalTrials.gov Identifier: NCT02229539.

AB - Importance: Oral mucositis causes substantial morbidity during head and neck radiotherapy. In a randomized study, doxepin mouthwash was shown to reduce oral mucositis-related pain. A common mouthwash comprising diphenhydramine-lidocaine-antacid is also widely used. Objective: To evaluate the effect of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash for the treatment of oral mucositis-related pain. Design, Setting, and Participants: A phase 3 randomized trial was conducted from November 1, 2014, to May 16, 2016, at 30 US institutions and included 275 patients who underwent definitive head and neck radiotherapy, had an oral mucositis pain score of 4 points or greater (scale, 0-10), and were followed up for a maximum of 28 days. Interventions: Ninety-two patients were randomized to doxepin mouthwash (25 mg/5 mL water); 91 patients to diphenhydramine-lidocaine-antacid; and 92 patients to placebo. Main Outcome and Measures: The primary end point was total oral mucositis pain reduction (defined by the area under the curve and adjusted for baseline pain score) during the 4 hours after a single dose of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash compared with a single dose of placebo. The minimal clinically important difference was a 3.5-point change. The secondary end points included drowsiness, unpleasant taste, and stinging or burning. All scales ranged from 0 (best) to 10 (worst). Results: Among the 275 patients randomized (median age, 61 years; 58 [21%] women), 227 (83%) completed treatment per protocol. Mucositis pain during the first 4 hours decreased by 11.6 points in the doxepin mouthwash group, by 11.7 points in the diphenhydramine-lidocaine-antacid mouthwash group, and by 8.7 points in the placebo group. The between-group difference was 2.9 points (95% CI, 0.2-6.0; P =.02) for doxepin mouthwash vs placebo and 3.0 points (95% CI, 0.1-5.9; P =.004) for diphenhydramine-lidocaine-antacid mouthwash vs placebo. More drowsiness was reported with doxepin mouthwash vs placebo (by 1.5 points [95% CI, 0-4.0]; P =.03), unpleasant taste (by 1.5 points [95% CI, 0-3.0]; P =.002), and stinging or burning (by 4.0 points [95% CI, 2.5-5.0]; P <.001). Maximum grade 3 adverse events for the doxepin mouthwash occurred in 3 patients (4%); diphenhydramine-lidocaine-antacid mouthwash, 3 (4%); and placebo, 2 (2%). Fatigue was reported by 5 patients (6%) in the doxepin mouthwash group and no patients in the diphenhydramine-lidocaine-antacid mouthwash group. Conclusions and Relevance: Among patients undergoing head and neck radiotherapy, the use of doxepin mouthwash or diphenhydramine-lidocaine-antacid mouthwash vs placebo significantly reduced oral mucositis pain during the first 4 hours after administration; however, the effect size was less than the minimal clinically important difference. Further research is needed to assess longer-term efficacy and safety for both mouthwashes. Trial Registration: ClinicalTrials.gov Identifier: NCT02229539.

UR - http://www.scopus.com/inward/record.url?scp=85064377661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064377661&partnerID=8YFLogxK

U2 - 10.1001/jama.2019.3504

DO - 10.1001/jama.2019.3504

M3 - Article

C2 - 30990550

AN - SCOPUS:85064377661

VL - 321

SP - 1481

EP - 1490

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 15

ER -